We use cookies for a better user experience. Read our Privacy Policy

I Agree

Acute Vulvovaginal Candidiasis Treatment Market

Acute Vulvovaginal Candidiasis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Acute Vulvovaginal Candidiasis Treatment: Introduction

  • Candidiasis is an infection caused by a yeast called candida. Symptoms of vaginal candidiasis include:
    • Vaginal itching or soreness
    • Pain during sexual intercourse
    • Pain or discomfort when urinating
    • Abnormal vaginal discharge
  • Vaginal yeast infection is a common fungal infection and is called candidal vaginitis or candidal vulvovaginitis (CVV). A healthy vagina normally has numerous bacteria and yeast cells. A common bacteria, named lactobacillus acidophilus, found in the vagina prevents the yeast cells from growing abnormally; however, sometimes due to certain factors, such as prolonged usage of antibiotics, compromised immunity, or lack of hygiene, can develop candida and cause yeast infection. Symptoms of vaginal yeast infection include itching, burning sensation or pain during urination or sexual intercourse, swelling, rashes, and redness. Earlier, yeast infections were not common and systemic or serious yeast infection were rare; however, revalence of yeast infections is rising rapidly due to the advent of broad-spectrum antibiotics and their widespread usage.

Key Drivers of Global Acute Vulvovaginal Candidiasis Treatment Market

  • The global acute vulvovaginal candidiasis treatment market is anticipated to expand at a significant rate during the forecast period owing to various factors. Rapid increase and unrestrained usage of antibiotics leading to high prevalence of yeast infection is expected to augment the demand for yeast infection treatment drugs globally.
  • Increase in the global burden of various ailments such as cardiovascular, neurological, and gastrointestinal diseases as well as cancer has boosted the consumption of broad-spectrum antibiotics, thereby propelling the number of yeast infection cases
  • Rapid increase in the global disease burden, coupled with escalating demand for better treatment options and increasing number of hospital-acquired infections, is also propelling the demand for acute vulvovaginal candidiasis treatment. Other factors driving the global acute vulvovaginal candidiasis treatment market are development of novel anti-fungal drugs, increase in healthcare expenditure, and development in healthcare infrastructure.

Clotrimazole Segment to Dominate Global Market

  • In terms of drug type, the global acute vulvovaginal candidiasis treatment market can be bifurcated into clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole, and others
  • The clotrimazole segment is expected to dominate the global market during the forecast period due to high efficiency and usage of clotrimazole drug for the treatment of acute vulvovaginal candidiasis

Oral Segment to Lead Global Market

  • Based on route of administration, the global acute vulvovaginal candidiasis treatment market can be classified into oral, intravenous, and topical. The oral segment is likely to dominate the global market during the forecast period, as most of the acute vulvovaginal candidiasis treatment drugs are taken orally.

Hospital Pharmacy to be Highly Lucrative Segment

  • In terms of distribution channel, the global acute vulvovaginal candidiasis treatment market can be categorized into hospital pharmacy, retail pharmacy, online pharmacy, and others
  • The hospital pharmacy segment is projected to account for a major share of the global acute vulvovaginal candidiasis treatment market by 2031 as a large number of patients treated in hospitals

North America to Offer Significant Opportunities in Acute Vulvovaginal Candidiasis Treatment Market

  • In terms of region, the global acute vulvovaginal candidiasis treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • In terms of revenue, the U.S. holds a major share of the acute vulvovaginal candidiasis treatment market in North America
  • The market in Europe is expanding rapidly, due to increase in the patient population, especially in the U.K. and Germany. Moreover, the market in Asia Pacific and Latin America is projected to expand significantly in the near future.
  • Developing economies such as China and Japan are projected to contribute to the expansion of the market in Asia Pacific due to better healthcare infrastructure, economic growth, increase in the number of insurance payers, expansion of the private healthcare sector, and increase in education and awareness.

Key Players Operating in Global Acute Vulvovaginal Candidiasis Treatment Market

The global acute vulvovaginal candidiasis treatment market is highly fragmented, with the presence of international and local players. Key players operating in the global acute vulvovaginal candidiasis treatment market are:

  • Mycovia Pharmaceuticals, Inc.
  • Scynexis, Inc.
  • Basilea Pharmaceutica Ltd.
  • Astellas Pharma Inc.
  • Grupo Ferrer Internacional, S.A.
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc.
  • Cidara Therapeutics, Inc.
  • Amplyx Pharmaceuticals Inc.
  • Pfizer, Inc.

Global Acute Vulvovaginal Candidiasis Treatment Market: Research Scope

Global Acute Vulvovaginal Candidiasis Treatment Market, by Drug Type

  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others

Global Acute Vulvovaginal Candidiasis Treatment Market, by Route of Administration

  • Oral
  • Intravenous
  • Topical

Global Acute Vulvovaginal Candidiasis Treatment Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Global Acute Vulvovaginal Candidiasis Treatment Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Interested in this report?
Get a FREE Brochure now!

Request Brochure

*Get Brochure (PDF) sent to your email within minutes

N/A

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

842

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved